Last reviewed · How we verify
NCT03923400
Jejunoileal vs Gastric GIST in the Era of Imatinib.
trial in Disease-free Survival in 77 participants. Completed in 31 January 2017.
31 January 2017
Quick facts
| Lead sponsor | Hospital Universitario Virgen de la Arrixaca |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 77 |
| Start date | 1 November 2016 |
| Primary completion | 31 January 2017 |
| Estimated completion | 31 January 2017 |
| Sites | 1 location across Spain |
Conditions studied
- Disease-free Survival — all drugs for Disease-free Survival →
- Overall Survival — all drugs for Overall Survival →
- Recurrence — all drugs for Recurrence →
Sponsor
Hospital Universitario Virgen de la Arrixaca
Who can join
18 and older, any sex, with Disease-free Survival or Overall Survival. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction: Gastrointestinal Stromal Tumors (GISTs) located in the jejunum or ileum (JI-GIST) are considered of worse prognosis compared to other locations. It has been suggested that this dogma should be revised. The aim of this study is to describe the characteristics of jejunoileal GISTs and its prognosis; and to compare them with gastric GISTs in the era of imatinib. Patients and methods: We retrospectively reviewed the clinical histories of all the patients diagnosed with GISTs between January 2000 and November 2016. Clinical and pathological data, as well recurrence, metastatic, disease-free survival (DFS) as overall (OS) rates of patients with JI-GIST or gastric GIST (G-GIST) were collected and compared.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03923400
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Disease-free Survival
Currently open trials in the same condition.
- NCT05436561 — Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies · Phase 2 · recruiting
- NCT06462742 — Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma · recruiting
Other Hospital Universitario Virgen de la Arrixaca trials
Trials by the same sponsor.
- NCT06933264 — Corporal Composition and Gut Microbiome Modification Through Exclusion Dietary Intervention in Crohn's Disease · NA · not yet recruiting
- NCT05688137 — Abdominal Drainage in the Postoperative Period of Liver Transplantation (DRALIT) · NA · unknown
- NCT04783844 — Usefulness of 3D Digital Reconstruction in the Imaging Diagnosis of Pancreatic Tumors · unknown
- NCT03870646 — Nebulized hypErtonic Saline for Better Prevention of mUcus pLug in Critical Adult Tracheostomized Patients · Phase 3 · unknown
- NCT04039659 — POstoperative Negative-pressure Incision Therapy Following LIver TRANSplant:a Randomized Controlled Trial · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03923400 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitario Virgen de la Arrixaca
- Last refreshed: 22 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03923400.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing